SAB Biotherapeutics, Inc. (SABS) NASDAQ
3.49
+0.05(+1.45%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
3.49
+0.05(+1.45%)
Currency In USD
| Market Cap | 72.23M |
| Enterprise Value | 67.67M |
| P/E Ratio | -469.14 |
| PEG Ratio | 14.28 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | 0.82 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | 10.88 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -0 |
| Return On Equity | -0 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | -3.08M |
| EBITDA | 16.6M |
| Net Income | 13.27M |
| Diluted EPS | -0.79 |
| Total Cash | 107.39M |
| Total Cash/Share | 2.01 |
| Total Debt | 6.17M |
| Total Debt/Equity | 0.03 |
| Current Ratio | 11.45 |
| Book Value Per Share | 4.24 |
| 52-Week Change | 81.77 |
| 52-Week High | 6.6 |
| 52-Week Low | 1.6 |
| Moving Average 50 Days | 3.77 |
| Moving Average 200 Days | 3.42 |
| Average Volume | 789,158 |
| Shares Outstanding | 9.56M |
| % Held by Institutions | 358.29 |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | 1:10 |
| Last Split Date | January 05, 2024 |